In another clinical study involving a smaller sample size of 51 healthy individuals and 41 patients with age-related cognitive impairment, it was evident that the plasma B2M content in patients with cognitive impairment was markedly higher compared to that of the healthy controls (Yang et al. 2017). The gene discussed is B2M; the disease is Cognitive impairment.